Business
CYP2C19-ID Kit used to support expansion
CYP2C19-ID Kit used to support expansion.
About this update from Genedrive Plc
[{"type":"text","content":"\n\ngenedrive plc\n(\"genedrive\" or the \"Company\")\n \nGenedrive® CYP2C19-ID Kit to be used to support expansion of use to include Acute Coronary Syndrome\n \ngenedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces the use of the Genedrive® CYP2C19-ID Kit in a trial led by Manchester University Foundation Trust (\"MFT\") in collaboration with the Genotype Guided Primary Coronary Intervention (\"GUIDE PCI\") programme and the British Heart Foundation (\"BHF\") Centre of Excellence, which aims to assess the value and feasibility of rapid point of care CYP2C19 testing in cardiovascular disease to improve patient outcomes. The sales value of the order is circa. £120K.\n \nCYP2C19 genotyping is already recommended by the National Institute for Health & Care Excellence (\"NICE\") prior to treatment with the antiplatelet Clopidogrel in Ischaemic Stroke (\"IS\") and Transient Ischaemic Attack (\"TIA\"), with the Genedrive® CYP2C19-ID kit recommended as the first line point of care test to be used in the UK NHS.\n \nThere are more than 7.6 million people living with a heart or circulatory disease in the UK, and over 100,000 hospital admissions each year due to heart attacks, with these patients often requiring lifelong antiplatelet therapy. The American Heart Association (\"AHA\") recently released a scientific statement recommending CYP2C19 genetic testing in cardiovascular indications such as Acute Coronary Syndrome (\"ACS\"), with an emphasis on results being available rapidly1. The GUIDE PCI programme at MFT aims to embed the Genedrive® CYP2C19-ID Kit into routine PCI clinical practice. Over a 12-month period, clinicians will use the Genedrive® CYP2C19-ID Kit for patients undergoing PCI, rapidly identifying which antiplatelet therapy they should receive. The programme will establish the feasibility and value of this intervention, supporting roll out at other centres.\n \nDr Gino Miele, CEO of genedrive plc, said: \"We are delighted that our CYP2C19 rapid genetic test is being assessed for use in ACS and PCI procedures in addition to current clinical recommendations by NICE for use prior to prescription of Clopidogrel in IS and TIA. With clinical recommendations for CYP2C19 genetic testing for IS, TIA and ACS, and with rapid genetic testing within 24 hours being recommende...